| Literature DB >> 23509778 |
Siyamak Ebrahimi Nigjeh1, Fatimah Md Yusoff, Noorjahan Banu Mohamed Alitheen, Mehdi Rasoli, Yeap Swee Keong, Abdul Rahman bin Omar.
Abstract
Marine microalgae have been prominently featured in cancer research. Here, we examined cytotoxic effect and apoptosis mechanism of crude ethanol extracts of an indigenous microalga, Chaetoceros calcitrans (UPMAAHU10) on human breast cell lines. MCF-7 was more sensitive than MCF-10A with IC50 value of 3.00 ± 0.65, whilst the IC50 value of Tamoxifen against MCF-7 was 12.00 ± 0.52 μg/mL after 24 hour incubation. Based on Annexin V/Propidium iodide and cell cycle flow cytometry analysis, it was found that inhibition of cell growth by EEC on MCF-7 cells was through the induction of apoptosis without cell cycle arrest. The apoptotic cells at subG0/G1 phase in treated MCF-7 cells at 48 and 72 hours showed 34 and 16 folds increased compared to extract treated MCF-10A cells which showed only 6 and 7 folds increased at the same time points, respectively. Based on GeXP study, EEC induced apoptosis on MCF-7 cells via modulation of CDK2, MDM2, p21Cip1, Cyclin A2, Bax and Bcl-2. The EEC treated MCF-7 cells also showed an increase in Bax/Bcl-2 ratio that in turn activated the caspase-dependent pathways by activating caspase 7. Thus, marine microalga, Chaetoceros calcitrans may be considered a good candidate to be developed as a new anti-breast cancer drug.Entities:
Mesh:
Substances:
Year: 2012 PMID: 23509778 PMCID: PMC3591159 DOI: 10.1155/2013/783690
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Selected apoptotic and cell cycle related genes used in GeXP assay.
| Gene | Accession number | Product size | Left sequence* | Right Sequence** |
|---|---|---|---|---|
| BCL2 | M14745 | 157 | ACCACTAATTGCCAAGCACC | TTTTCCATCCGTCTGCTCTT |
| Fas | NM_000043 | 165 | CTCCAAGGGATTGGAATTGA | TGCAGTCCCTAGCTTTCCTT |
| TNF alpha | NM_000594 | 171 | CTATCTGGGAGGGGTCTTCC | ATGTTCGTCCTCCTCACAGG |
| Caspase 3 | NM_004346 | 182 | GAACTGGACTGTGGCATTGA | ACCAGGAGCCATCCTTTGA |
| p21Cip1 | NM_000389 | 202 | TGTGGACCTGTCACTGTCTTG | TAGGGCTTCCTCTTGGAGAA |
| Cyclin A2 | NM_001237 | 212 | TATTGCTGGAGCTGCCTTTC | CTTTTCTCTTATTGACTGTTGTGCAT |
| BCL2L1 | NM_001191 | 232 | CCACAGCAGCAGTTTGGAT | GGGATTGTTCCCATAGAGTTCCACAA |
| MDM2 | NM_002392 | 239 | GGTGGGAGTGATCAAAAGGA | ACCAGGCTTTCATCAAAGGAA |
| Caspase 7 | NM_033340 | 247 | CAGACCGGTCCTCGTTTGTA | ACCTCGGCATCTTTGTCTGTT |
| CDK2 | NM_052827 | 285 | TGGTGGCGCTTAAGAAAATC | ACAGCTGGAACAGATAGCTCTTGA |
| ACTBa | NM_001101 | 295 | CTGGCACCACACCTTCTACA | AAGGGCATACCCCTCGTAGAT |
| Bax | BC014175 | 316 | CCCTTTTGCTTCAGGGTTTC | ACAAAGTAGAAAAGGGCGACAA |
| KANb | Kan(r) | 325 | ATCATCAGCATTGCATTCGATTCCTGTTTG | AATTCCGACTCGTCCAACATC |
| Caspase 9 | NM_001229 | 332 | GGGCTCACTCTGAAGACCTG | ATCTGGAAGCTGCTAAGAGCC |
| P53 | NM_000546 | 340 | TTTTGGGTTTTGGGTCTTTG | ATTCAACATGAGGGACAGCTT |
*Forward universal primer sequence (AGGTGACACTATAGAATA).
**Reverse universal primer sequence (GTACGACTCACTATAGGGA).
aGene used for normalization.
bInternal control.
IC50 of EEC and Tamoxifen on MCF-7 cells.
| IC50 ( | ||
|---|---|---|
| 24 hour | 72 hour | |
| EEC treated MCF-7 | 3.00 ± 0.65 | 2.69 ± 0.24 |
| EEC treated MCF10A | 12.00 ± 0.59 | 3.30 ± 0.36 |
| EEC treated PBMC | >30 | >30 |
| Tamoxifen treated MCF-7 | 12.00 ± 0.52 | 9.00 ± 0.40 |
Values are expressed as mean ± S.E. from triplicate.
Figure 1Morphology changes of MCF-7 cells after EEC treatment for 24 (a) and 72 (c) hours. Treated cells were rounded up and cell to cell adhesion was lost. Arrows show membrane blebbing and rounded cells at 40x magnification. The black bar in each image represents 10 μm.
Figure 2Annexin V/PI study on MCF-7 cell treated with IC50 and IC75 of EEC for 12 and 24 hours.
Figure 3Fold change analysis of gene expressions in MCF-7 cells after 6- and 24-hour treatment with EEC. The lowest fold change 0.8 in p21Cip1 and the highest fold change 3.4 in Cyclin A2 at 6 hours of treatment.
Figure 4Fold change analysis of gene expressions in MCF-10A cells after 6- and 24-hour treatments with EEC. The lowest fold change 0.4 in CDK2 and the highest fold change 1.3 in p21Cip1 at 24 hours of treatment.
(a)
| MCF-7 cells Cell cycle phases (Percentage) | ||||
|---|---|---|---|---|
| G0/G1 | G2/M | S | SubG0/G1 | |
| Control* | ||||
|
| 61.42 ± 0.07 | 17.12 ± 0.24 | 22.48 ± 0.19 | 0.39 ± 0.008 |
|
| 63.38 ± 0.43 | 14.19 ± 0.21 | 14.67 ± 0.40 | 1.62 ± 0.11 |
|
| 87.17 ± 0.13 | 1.63 ± 0.04 | 6.07 ± 0.03 | 4.53 ± 0.12 |
| IC50-3 | ||||
| 24 hours | 64.82 ± 0.32 | 12.93 ± 0.56 | 21.24 ± 0.30 | 2.31 ± 0.13 |
| 48 hours | 44.6 ± 1.37a | 0.01 ± 0.005a | 0.46 ± 0.02a | 55.75 ± 1.25a |
| 72 hours | 27.85 ± 1.26a | 0.02 ± 0.01 | 0.35 ± 0.02a | 72.75 ± 1.23a |
Values are expressed as mean ± S.E. (Standard Error), μg/mL. (P < 0.001, ANOVA).
*Untreated cells were used as a control. aSignificant difference with untreated group (P < 0.05).
(b)
| MCF-10A Cell cycle phases (Percentage) | ||||
|---|---|---|---|---|
| G0/G1 | G2/M | S | Sub G0/G1 | |
| Control* | ||||
| 24 hours | 63.45 ± 1.70 | 14.16 ± 1.01 | 17.20 ± 0.75 | 4.10 ± 0.14 |
| 48 hours | 62.25 ± 1.39 | 12.68 ± 0.51 | 16.10 ± 0.20 | 4.50 ± 0.08 |
| 72 hours | 58.12 ± 1.01 | 11.38 ± 0.29 | 20.45 ± 1.22 | 5.00 ± 0.18 |
| IC50-3 | ||||
| 24 hours | 60.49 ± 1.06 | 3.84 ± 0.12 | 16.37 ± 0.22 | 17.52 ± 0.57 |
| 48 hours | 53.39 ± 0.69 | 6.4 ± 0.008 | 12.25 ± 0.29 | 27.24 ± 0.40 |
| 72 hours | 44.76 ± 0.77 | 5.91 ± 0.21 | 10.63 ± 0.34 | 37.18 ± 0.53 |
Values are expressed as mean ± S.E. (Standard Error), μg/mL. (P < 0.001, ANOVA).